[
  {
    "": 0,
    "__1": 0,
    "Gene name": "RB1",
    "Genomic Position": "13:48877911-49056122(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Alpelisib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:25002028"
  },
  {
    "": 1,
    "__1": 1,
    "Gene name": "RB1",
    "Genomic Position": "13:48877911-49056122(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Alpelisib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:25002028"
  },
  {
    "": 2,
    "__1": 2,
    "Gene name": "RB1",
    "Genomic Position": "13:48877911-49056122(+)",
    "CDS Mutation": "PHOSPHORYLATION",
    "AA Mutation": "p.PHOSPHORYLATION",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Resistance",
    "Therapies": "Alpelisib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:25002028"
  },
  {
    "": 3,
    "__1": 3,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_and_ERBB2_unspecified",
    "AA Mutation": "unspecified_and_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 4,
    "__1": 4,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 5,
    "__1": 5,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Triple-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 6,
    "__1": 6,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 7,
    "__1": 7,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 8,
    "__1": 8,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 9,
    "__1": 9,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 10,
    "__1": 10,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
    "AA Mutation": "unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 11,
    "__1": 11,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 12,
    "__1": 12,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Her2-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 13,
    "__1": 13,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "Loss-of-function",
    "AA Mutation": "Loss-of-function",
    "Disease": "Her2-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 14,
    "__1": 14,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "Loss-of-function",
    "AA Mutation": "Loss-of-function",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 15,
    "__1": 15,
    "Gene name": "BRCA1",
    "Genomic Position": "17:41197646-41277500(-)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Triple-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Resistance",
    "Therapies": "Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05485766"
  },
  {
    "": 16,
    "__1": 16,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "Amplification",
    "AA Mutation": "Amplification",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 17,
    "__1": 17,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 18,
    "__1": 18,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_WT1_unspecified",
    "AA Mutation": "unspecified_and_WT1_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 19,
    "__1": 19,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
    "AA Mutation": "unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 20,
    "__1": 20,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_ESR1_unspecified",
    "AA Mutation": "unspecified_and_ESR1_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 21,
    "__1": 21,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_GATA3_unspecified",
    "AA Mutation": "unspecified_and_GATA3_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 22,
    "__1": 22,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_PIK3CA_unspecified",
    "AA Mutation": "unspecified_and_PIK3CA_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 23,
    "__1": 23,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_PTEN_unspecified",
    "AA Mutation": "unspecified_and_PTEN_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 24,
    "__1": 24,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_TBX3_unspecified",
    "AA Mutation": "unspecified_and_TBX3_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 25,
    "__1": 25,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_TOP2A_unspecified",
    "AA Mutation": "unspecified_and_TOP2A_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 26,
    "__1": 26,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_TP53_unspecified",
    "AA Mutation": "unspecified_and_TP53_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 27,
    "__1": 27,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_TP53_unspecified_",
    "AA Mutation": "unspecified_and_TP53_unspecified_",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 28,
    "__1": 28,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "Overexpression",
    "AA Mutation": "Overexpression",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 29,
    "__1": 29,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "SERUM_LEVELS",
    "AA Mutation": "SERUM_LEVELS",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 30,
    "__1": 30,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_ERBB2_unspecified",
    "AA Mutation": "unspecified_and_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 31,
    "__1": 31,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "Exon19,Exon20",
    "AA Mutation": "Exon19,Exon20",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 32,
    "__1": 32,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 2,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 33,
    "__1": 33,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 34,
    "__1": 34,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "Amplification",
    "AA Mutation": "Amplification",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 35,
    "__1": 35,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 36,
    "__1": 36,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_NRG1_unspecified",
    "AA Mutation": "unspecified_and_NRG1_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 37,
    "__1": 37,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_ERBB3_unspecified",
    "AA Mutation": "unspecified_and_ERBB3_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 38,
    "__1": 38,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified_and_PIK3CA_unspecified",
    "AA Mutation": "unspecified_and_PIK3CA_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 39,
    "__1": 39,
    "Gene name": "ERBB2",
    "Genomic Position": "17:37856333-37884915(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma in situ / ductal carcinoma in situ",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "H2NVAC + Sargramostim",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04144023"
  },
  {
    "": 40,
    "__1": 40,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 41,
    "__1": 41,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 42,
    "__1": 42,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "unspecified_or_PTEN_unspecified_or_TP53_unspecified",
    "AA Mutation": "unspecified_or_PTEN_unspecified_or_TP53_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 43,
    "__1": 43,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 44,
    "__1": 44,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "c.3140A>G",
    "AA Mutation": "p.H1047R",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": 121913279,
    "pmid": "PubMed:27445490"
  },
  {
    "": 45,
    "__1": 45,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 46,
    "__1": 46,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 47,
    "__1": 47,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "c.1634A>G",
    "AA Mutation": "p.E545",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": 121913274,
    "pmid": "PubMed:27445490"
  },
  {
    "": 48,
    "__1": 48,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "H1047X",
    "AA Mutation": "p.H1047X",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 49,
    "__1": 49,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "c.1624G>A",
    "AA Mutation": "p.E542K",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": 121913273,
    "pmid": "PubMed:27445490"
  },
  {
    "": 50,
    "__1": 50,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "unspecified_or_PTEN_unspecified",
    "AA Mutation": "unspecified_or_PTEN_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 51,
    "__1": 51,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 52,
    "__1": 52,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 53,
    "__1": 53,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "Exon9_or_PIK3CA_Exon20",
    "AA Mutation": "Exon9_or_PIK3CA_Exon20",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 54,
    "__1": 54,
    "Gene name": "PIK3CA",
    "Genomic Position": "3:178866311-178957881(+)",
    "CDS Mutation": "c.3140A>G",
    "AA Mutation": "p.H1047R",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Sensitivity",
    "Therapies": "Fulvestrant,Everolimus",
    "Description": "",
    "rs value": 121913279,
    "pmid": "PubMed:27445490"
  },
  {
    "": 55,
    "__1": 55,
    "Gene name": "AKT2",
    "Genomic Position": "19:40736224-40791302(-)",
    "CDS Mutation": "EXPRESSION",
    "AA Mutation": "EXPRESSION",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Trastuzumab",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:22842582"
  },
  {
    "": 56,
    "__1": 56,
    "Gene name": "IGF1R",
    "Genomic Position": "15:99192200-99507759(+)",
    "CDS Mutation": "Overexpression",
    "AA Mutation": "Overexpression",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Metformin,Exemestane",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26706833"
  },
  {
    "": 57,
    "__1": 57,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "c.745A>T",
    "AA Mutation": "p.R249",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": 587782082,
    "pmid": "PubMed:10786679"
  },
  {
    "": 58,
    "__1": 58,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "DNA_Binding_Domain_Mutation",
    "AA Mutation": "DNA_Binding_Domain_Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Resistance",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:10786679"
  },
  {
    "": 59,
    "__1": 59,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "deletion_and_PDCD4_unspecified",
    "AA Mutation": "deletion_and_PDCD4_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:10786679"
  },
  {
    "": 60,
    "__1": 60,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:10786679"
  },
  {
    "": 61,
    "__1": 61,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:10786679"
  },
  {
    "": 62,
    "__1": 62,
    "Gene name": "TP53",
    "Genomic Position": "17:7571720-7590856(-)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Resistance",
    "Therapies": "Tamoxifen",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:10786679"
  },
  {
    "": 63,
    "__1": 63,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
    "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 64,
    "__1": 64,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "Amplification",
    "AA Mutation": "Amplification",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 65,
    "__1": 65,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
    "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 66,
    "__1": 66,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 67,
    "__1": 67,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
    "AA Mutation": "unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 68,
    "__1": 68,
    "Gene name": "FGFR1",
    "Genomic Position": "8:38268656-38325363(-)",
    "CDS Mutation": "Amplification",
    "AA Mutation": "Amplification",
    "Disease": "Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Sensitivity",
    "Therapies": "FGFR Inhibitor AZD4547",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27179038"
  },
  {
    "": 69,
    "__1": 69,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "Overexpression",
    "AA Mutation": "Overexpression",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 70,
    "__1": 70,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 71,
    "__1": 71,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / ER-positive carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 72,
    "__1": 72,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "c.851-26475A>G",
    "AA Mutation": "p.?",
    "Disease": "ductal_carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 73,
    "__1": 73,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "c.1613A>G",
    "AA Mutation": "p.D538G",
    "Disease": "ductal_carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 74,
    "__1": 74,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "c.830A>G",
    "AA Mutation": "p.D277G",
    "Disease": "ductal_carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 75,
    "__1": 75,
    "Gene name": "ESR1",
    "Genomic Position": "6:152011631-152424409(+)",
    "CDS Mutation": "c.*488A>G",
    "AA Mutation": "p.?",
    "Disease": "ductal_carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Endocrine therapy",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:24217577"
  },
  {
    "": 76,
    "__1": 76,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "Loss",
    "AA Mutation": "Loss",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 77,
    "__1": 77,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 78,
    "__1": 78,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 79,
    "__1": 79,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "Loss",
    "AA Mutation": "Loss",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Resistance",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 80,
    "__1": 80,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "Expression",
    "AA Mutation": "Expression",
    "Disease": "Breast Cancer",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 81,
    "__1": 81,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 82,
    "__1": 82,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "Loss",
    "AA Mutation": "Loss",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 83,
    "__1": 83,
    "Gene name": "PTEN",
    "Genomic Position": "10:89622870-89731687(+)",
    "CDS Mutation": "Expression",
    "AA Mutation": "Expression",
    "Disease": "Her2-receptor Positive Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Resistance",
    "Therapies": "Everolimus,Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:27445490"
  },
  {
    "": 84,
    "__1": 84,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26351323"
  },
  {
    "": 85,
    "__1": 85,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26351323"
  },
  {
    "": 86,
    "__1": 86,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
    "AA Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26351323"
  },
  {
    "": 87,
    "__1": 87,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
    "AA Mutation": "unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26351323"
  },
  {
    "": 88,
    "__1": 88,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "c.49G>A",
    "AA Mutation": "p.E17K",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": 121434592,
    "pmid": "PubMed:26351323"
  },
  {
    "": 89,
    "__1": 89,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "AA Mutation": "unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26351323"
  },
  {
    "": 90,
    "__1": 90,
    "Gene name": "AKT1",
    "Genomic Position": "14:105235686-105260461(-)",
    "CDS Mutation": "c.49G>A",
    "AA Mutation": "p.E17K",
    "Disease": "Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capivasertib",
    "Description": "",
    "rs value": 121434592,
    "pmid": "PubMed:26351323"
  },
  {
    "": 91,
    "__1": 91,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "unspecified_and_ERBB2_unspecified",
    "AA Mutation": "unspecified_and_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 92,
    "__1": 92,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Triple-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 93,
    "__1": 93,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "Loss-of-function",
    "AA Mutation": "Loss-of-function",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 94,
    "__1": 94,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "Loss-of-function",
    "AA Mutation": "Loss-of-function",
    "Disease": "Her2-receptor Negative Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 95,
    "__1": 95,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "Mutation",
    "AA Mutation": "Mutation",
    "Disease": "Breast Cancer",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 96,
    "__1": 96,
    "Gene name": "BRCA2",
    "Genomic Position": "13:32889617-32973805(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 97,
    "__1": 97,
    "Gene name": "ETV6",
    "Genomic Position": "12:11802788-12048336(+)",
    "CDS Mutation": "ETV6::NTRK3",
    "AA Mutation": "p.ETV6::NTRK3",
    "Disease": "Breast Secretory Carcinoma",
    "therapy_rank": 4,
    "Response to Drug": "Sensitivity",
    "Therapies": "Larotrectinib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:29623306"
  },
  {
    "": 98,
    "__1": 98,
    "Gene name": "CDKN2A",
    "Genomic Position": "9:21968055-21974865(-)",
    "CDS Mutation": "Loss",
    "AA Mutation": "Loss",
    "Disease": "Her2-receptor Negative Breast Cancer",
    "therapy_rank": 4,
    "Response to Drug": "Sensitivity",
    "Therapies": "Letrozole,Palbociclib",
    "Description": "",
    "rs value": "",
    "pmid": "PubMed:26715889"
  },
  {
    "": 99,
    "__1": 99,
    "Gene name": "BARD1",
    "Genomic Position": "2:215590370-215674428(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Talazoparib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04892693"
  },
  {
    "": 100,
    "__1": 100,
    "Gene name": "PPP2R2A",
    "Genomic Position": "8:26150732-26228402(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Talazoparib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04892693"
  },
  {
    "": 101,
    "__1": 101,
    "Gene name": "ERBB3",
    "Genomic Position": "12:56473645-56497289(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Patritumab deruxtecan",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02980341"
  },
  {
    "": 102,
    "__1": 102,
    "Gene name": "CHEK2",
    "Genomic Position": "22:29083751-29137826(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 103,
    "__1": 103,
    "Gene name": "EGFR",
    "Genomic Position": "7:55086794-55279321(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Gefitinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT01732276"
  },
  {
    "": 104,
    "__1": 104,
    "Gene name": "EGFR",
    "Genomic Position": "7:55086794-55279321(+)",
    "CDS Mutation": "unspecified_and_ERBB2_unspecified",
    "AA Mutation": "unspecified_and_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Gefitinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT01732276"
  },
  {
    "": 105,
    "__1": 105,
    "Gene name": "EGFR",
    "Genomic Position": "7:55086794-55279321(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Gefitinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT01732276"
  },
  {
    "": 106,
    "__1": 106,
    "Gene name": "EGFR",
    "Genomic Position": "7:55086794-55279321(+)",
    "CDS Mutation": "unspecified_or_ERBB2_unspecified",
    "AA Mutation": "unspecified_or_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Gefitinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT01732276"
  },
  {
    "": 107,
    "__1": 107,
    "Gene name": "EGFR",
    "Genomic Position": "7:55086794-55279321(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Gefitinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT01732276"
  },
  {
    "": 108,
    "__1": 108,
    "Gene name": "ERBB4",
    "Genomic Position": "2:212240446-213403565(-)",
    "CDS Mutation": "unspecified_and_CD274_unspecified",
    "AA Mutation": "unspecified_and_CD274_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04872985"
  },
  {
    "": 109,
    "__1": 109,
    "Gene name": "ERBB4",
    "Genomic Position": "2:212240446-213403565(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04872985"
  },
  {
    "": 110,
    "__1": 110,
    "Gene name": "ERBB4",
    "Genomic Position": "2:212240446-213403565(-)",
    "CDS Mutation": "unspecified_and_CD274_unspecified",
    "AA Mutation": "unspecified_and_CD274_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04872985"
  },
  {
    "": 111,
    "__1": 111,
    "Gene name": "FGFR3",
    "Genomic Position": "4:1795039-1810599(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Futibatinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04024436"
  },
  {
    "": 112,
    "__1": 112,
    "Gene name": "BCL2",
    "Genomic Position": "18:60790579-60987361(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Letrozole + Palbociclib + Venetoclax",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT03900884"
  },
  {
    "": 113,
    "__1": 113,
    "Gene name": "ALK",
    "Genomic Position": "2:29415640-30144432(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Crizotinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02034981"
  },
  {
    "": 114,
    "__1": 114,
    "Gene name": "CDK12",
    "Genomic Position": "17:37618292-37691399(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Talazoparib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04892693"
  },
  {
    "": 115,
    "__1": 115,
    "Gene name": "MTOR",
    "Genomic Position": "1:11166592-11322564(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Vistusertib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02299999"
  },
  {
    "": 116,
    "__1": 116,
    "Gene name": "CD274",
    "Genomic Position": "9:5450525-5470547(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Avelumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02926196"
  },
  {
    "": 117,
    "__1": 117,
    "Gene name": "CD274",
    "Genomic Position": "9:5450525-5470547(+)",
    "CDS Mutation": "unspecified_and_ERBB2_unspecified",
    "AA Mutation": "unspecified_and_ERBB2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Avelumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02926196"
  },
  {
    "": 118,
    "__1": 118,
    "Gene name": "CD274",
    "Genomic Position": "9:5450525-5470547(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Avelumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02926196"
  },
  {
    "": 119,
    "__1": 119,
    "Gene name": "CD274",
    "Genomic Position": "9:5450525-5470547(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / basal (triple-negative) carcinoma",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Avelumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02926196"
  },
  {
    "": 120,
    "__1": 120,
    "Gene name": "CD274",
    "Genomic Position": "9:5450525-5470547(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Avelumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT02926196"
  },
  {
    "": 121,
    "__1": 121,
    "Gene name": "RET",
    "Genomic Position": "10:43572475-43625799(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Lenvatinib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT03168074"
  },
  {
    "": 122,
    "__1": 122,
    "Gene name": "RAD51D",
    "Genomic Position": "17:33427691-33446832(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  },
  {
    "": 123,
    "__1": 123,
    "Gene name": "ROS1",
    "Genomic Position": "6:117609463-117747018(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Crizotinib + Fulvestrant",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT03620643"
  },
  {
    "": 124,
    "__1": 124,
    "Gene name": "NF1",
    "Genomic Position": "17:29421945-29704695(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Famitinib + SHR7390",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04355858"
  },
  {
    "": 125,
    "__1": 125,
    "Gene name": "KRAS",
    "Genomic Position": "12:25362365-25403737(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Paclitaxel + Pelareorep",
    "Description": "",
    "rs value": "",
    "pmid": "Corporate website:NCT01656538"
  },
  {
    "": 126,
    "__1": 126,
    "Gene name": "KRAS",
    "Genomic Position": "12:25362365-25403737(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Paclitaxel + Pelareorep",
    "Description": "",
    "rs value": "",
    "pmid": "Corporate website:NCT01656538"
  },
  {
    "": 127,
    "__1": 127,
    "Gene name": "PDGFRB",
    "Genomic Position": "5:149493400-149535423(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Famitinb",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04355858"
  },
  {
    "": 128,
    "__1": 128,
    "Gene name": "BRIP1",
    "Genomic Position": "17:59758627-59940882(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Talazoparib",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04892693"
  },
  {
    "": 129,
    "__1": 129,
    "Gene name": "ATM",
    "Genomic Position": "11:108093559-108239826(+)",
    "CDS Mutation": "unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
    "AA Mutation": "unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 1,
    "Response to Drug": "Sensitivity",
    "Therapies": "Olaparib + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05033756"
  },
  {
    "": 130,
    "__1": 130,
    "Gene name": "ATM",
    "Genomic Position": "11:108093559-108239826(+)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Olaparib + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05033756"
  },
  {
    "": 131,
    "__1": 131,
    "Gene name": "ATM",
    "Genomic Position": "11:108093559-108239826(+)",
    "CDS Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "AA Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Olaparib + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05033756"
  },
  {
    "": 132,
    "__1": 132,
    "Gene name": "ATM",
    "Genomic Position": "11:108093559-108239826(+)",
    "CDS Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
    "AA Mutation": "unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Olaparib + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05033756"
  },
  {
    "": 133,
    "__1": 133,
    "Gene name": "ATM",
    "Genomic Position": "11:108093559-108239826(+)",
    "CDS Mutation": "unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
    "AA Mutation": "unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Olaparib + Pembrolizumab",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT05033756"
  },
  {
    "": 134,
    "__1": 134,
    "Gene name": "PALB2",
    "Genomic Position": "16:23614491-23652631(-)",
    "CDS Mutation": "unspecified",
    "AA Mutation": "unspecified",
    "Disease": "breast / carcinoma / NS",
    "therapy_rank": 3,
    "Response to Drug": "Sensitivity",
    "Therapies": "Capecitabine + Platinum-based chemotherapy",
    "Description": "",
    "rs value": "",
    "pmid": "ClinicalTrials.gov:NCT04335669"
  }
]
